Apogee Therapeutics (APGE) News Today → The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (From Smallcaps Daily) (Ad) Free APGE Stock Alerts $53.30 -0.70 (-1.30%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 2:10 AM | americanbankingnews.comApogee Therapeutics, Inc. (NASDAQ:APGE) to Post Q2 2024 Earnings of ($0.59) Per Share, Wedbush ForecastsMay 15 at 4:01 PM | globenewswire.comApogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory DiseasesMay 15 at 7:49 AM | marketbeat.comBrokers Issue Forecasts for Apogee Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:APGE)Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) - Analysts at Wedbush upped their Q2 2024 earnings per share estimates for shares of Apogee Therapeutics in a research note issued to investors on Monday, May 13th. Wedbush analyst D. Nierengarten now anticipates that the company will post earMay 15 at 5:58 AM | americanbankingnews.comApogee Therapeutics, Inc. (NASDAQ:APGE) Expected to Post Q1 2025 Earnings of ($0.63) Per ShareMay 15 at 4:54 AM | americanbankingnews.comWedbush Reaffirms Outperform Rating for Apogee Therapeutics (NASDAQ:APGE)May 14 at 6:02 PM | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Sees Large Volume IncreaseApogee Therapeutics (NASDAQ:APGE) Sees Strong Trading VolumeMay 14 at 8:25 AM | marketbeat.comResearch Analysts Issue Forecasts for Apogee Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:APGE)Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) - Equities researchers at Wedbush issued their Q1 2025 EPS estimates for Apogee Therapeutics in a research note issued to investors on Monday, May 13th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.63)May 14 at 2:34 AM | markets.businessinsider.comBuy Rating on Apogee Therapeutics: Promising Drug Developments and Strong FinancialsMay 13 at 5:32 PM | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Stock Rating Reaffirmed by WedbushWedbush reaffirmed an "outperform" rating and issued a $87.00 price target on shares of Apogee Therapeutics in a research report on Monday.May 13 at 2:33 PM | investorplace.comAPGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024May 13 at 7:00 AM | globenewswire.comApogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial ResultsMay 12, 2024 | americanbankingnews.comBank of America Initiates Coverage on Apogee Therapeutics (NASDAQ:APGE)May 12, 2024 | americanbankingnews.comApogee Therapeutics (NASDAQ:APGE) Shares Gap Up to $52.92May 11, 2024 | nasdaq.comB of A Securities Initiates Coverage of Apogee Therapeutics (APGE) with Buy RecommendationMay 10, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Now Covered by Bank of AmericaBank of America began coverage on Apogee Therapeutics in a research note on Friday. They issued a "buy" rating and a $80.00 price target for the company.May 8, 2024 | investorplace.comEarnings Superstars: 3 Stocks Primed to Outperform This QuarterMay 6, 2024 | globenewswire.comApogee Therapeutics to Participate at the 2024 Bank of America Healthcare ConferenceApril 27, 2024 | marketbeat.comJennison Associates LLC Invests $2.90 Million in Apogee Therapeutics, Inc. (NASDAQ:APGE)Jennison Associates LLC acquired a new stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 103,744 shares of the company's stock,April 24, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Trading Down 6.2%Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 6.2%April 18, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Trading Down 6.1%Apogee Therapeutics (NASDAQ:APGE) Shares Down 6.1%April 17, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Stock Price Up 3.3%Apogee Therapeutics (NASDAQ:APGE) Shares Up 3.3%April 16, 2024 | finance.yahoo.comWith 54% institutional ownership, Apogee Therapeutics, Inc. (NASDAQ:APGE) is a favorite amongst the big gunsApril 15, 2024 | finance.yahoo.comApogee Therapeutics, Inc. (APGE)April 14, 2024 | marketbeat.comVanguard Group Inc. Makes New Investment in Apogee Therapeutics, Inc. (NASDAQ:APGE)Vanguard Group Inc. acquired a new stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,121,764 shares of the companApril 12, 2024 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest UpdateApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 4,600,000 shares, a growth of 50.8% from the March 15th total of 3,050,000 shares. Approximately 13.1% of the shares of the company are sold short. Based on an average trading volume of 680,700 shares, the days-to-cover ratio is currently 6.8 days.April 11, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Trading Up 7%Apogee Therapeutics (NASDAQ:APGE) Trading Up 7%April 9, 2024 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) Receives Average Recommendation of "Buy" from BrokeragesShares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) have been assigned an average rating of "Buy" from the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 12-month pricApril 8, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Stock Price Down 3.2%Apogee Therapeutics (NASDAQ:APGE) Trading Down 3.2%April 2, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Trading Down 9.1%Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 9.1%March 29, 2024 | finance.yahoo.comKey Proteo Submits De Novo Application to FDA for its First Newborn Screening KitMarch 28, 2024 | msn.comGov. Youngkin vetoes bills that would legalize retail marijuana sales, increase minimum wageMarch 28, 2024 | finance.yahoo.comUS FDA extends review of Applied Therapeutics' genetic disease drugMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Apogee Therapeutics as APG777 Shows Promise and Pipeline ProgressesMarch 25, 2024 | globenewswire.comApogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory DiseasesMarch 22, 2024 | marketbeat.comTeachers Retirement System of The State of Kentucky Takes $474,000 Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)Teachers Retirement System of The State of Kentucky purchased a new stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 22,248 shares of the compMarch 18, 2024 | marketbeat.comShort Interest in Apogee Therapeutics, Inc. (NASDAQ:APGE) Declines By 5.2%Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) was the recipient of a large decrease in short interest in February. As of February 29th, there was short interest totalling 3,130,000 shares, a decrease of 5.2% from the February 14th total of 3,300,000 shares. Approximately 14.6% of the company's stock are sold short. Based on an average trading volume of 513,400 shares, the short-interest ratio is presently 6.1 days.March 15, 2024 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) Given Average Rating of "Buy" by AnalystsApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) has been assigned an average recommendation of "Buy" from the seven brokerages that are covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average twelve-month target price among broMarch 14, 2024 | benzinga.comTop 3 Health Care Stocks That Are Ticking Portfolio BombsMarch 13, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Hits New 1-Year High at $71.80Apogee Therapeutics (NASDAQ:APGE) Sets New 52-Week High at $71.80March 13, 2024 | seekingalpha.comARM: Everything You Need To Know About The Lock-Up Expiry (Rating Upgrade)March 12, 2024 | finance.yahoo.comApogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 MillionMarch 12, 2024 | globenewswire.comApogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 MillionMarch 10, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Buys Shares of 375,000 Apogee Therapeutics, Inc. (NASDAQ:APGE)Adage Capital Partners GP L.L.C. bought a new stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 375,000 shares of the company's stock, valued at approximatMarch 8, 2024 | msn.comApogee Therapeutics stock slides on pricing upsized stock offering to raise $420 millionMarch 8, 2024 | finanznachrichten.deApogee Therapeutics, Inc.: Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | edition.cnn.comApogee Therapeutics, Inc.March 7, 2024 | globenewswire.comApogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public OfferingMarch 7, 2024 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Sets New 52-Week High Following Analyst UpgradeApogee Therapeutics (NASDAQ:APGE) Reaches New 12-Month High Following Analyst UpgradeMarch 7, 2024 | marketbeat.comWedbush Equities Analysts Lower Earnings Estimates for Apogee Therapeutics, Inc. (NASDAQ:APGE)Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) - Investment analysts at Wedbush cut their Q1 2024 earnings per share (EPS) estimates for shares of Apogee Therapeutics in a research note issued on Tuesday, March 5th. Wedbush analyst D. Nierengarten now forecasts that the company will post eMarch 6, 2024 | realmoney.thestreet.comApogee Therapeutics price target raised by $47 at Guggenheim, here's why Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (Ad)Nanoviricides Technology Will Transform The Way Viruses & Their Variants Are Treated Worldwide And This Company Is At The Forefront! See how with its ongoing expansion and development APGE Media Mentions By Week APGE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APGE News Sentiment▼0.470.55▲Average Medical News Sentiment APGE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APGE Articles This Week▼263▲APGE Articles Average Week Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VCEL News Today KYMR News Today TWST News Today RXRX News Today CGON News Today DNA News Today DNLI News Today BEAM News Today FUSN News Today INBX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APGE) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
